Business

Aeterna Zentaris to Present at Needham Healthcare Conference in New York

QUÉBEC CITY, March 29, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:&...

articleCosciens Biopharma Inc.March 29, 20125/company/cosciens-biopharma-inc/news/aeterna-zentaris-to-present-at-needham-healthcare-conference-in-new-york
Aeterna Zentaris to Present at Needham Healthcare Conference in New York

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, March 29, 2012 /CNW Telbec/ - Aeterna Zentaris Inc.\n (NASDAQ: AEZS) (TSX: AEZ) (the \"Company\") today announced that its\n President and CEO, Juergen Engel, PhD, will be presenting a corporate\n overview at the 11th Annual Needham Healthcare Conference on Wednesday, April 4, 2012, at\n 1:20 pm (Eastern), in the Henry Room of the New York Palace Hotel, in\n New York City.\n\n\nA live webcast of this slide presentation will be available on Aeterna\n Zentaris' website at www.aezsinc.com, in the Newsroom section. A replay of the webcast will also be\n available on the Company's website for a period of 90 days.\n\n\nAbout Aeterna Zentaris Inc.\n\n\nAeterna Zentaris is a late-stage oncology drug development company\n currently investigating potential treatments for various cancers\n including colorectal, multiple myeloma, endometrial, ovarian, prostate\n and bladder cancer. The Company's innovative approach of \"personalized\n medicine\" means tailoring treatments to a patient's specific condition\n and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn\n from its proprietary discovery unit providing the Company with constant\n and long-term access to state-of-the-art therapeutic options. For more\n information please visit www.aezsinc.com.\n\n\n\n\n\n\n Investor Relations Ginette Beaudet Vallières Investor Relations Coordinator (418) 652-8525 ext. [email protected] Media Relations Paul Burroughs Director of Communications (418) 652-8525 ext. [email protected] \n","length":1829,"tagName":"div"}]

More updates from Cosciens Biopharma Inc.